{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:50:44Z","timestamp":1786449044110,"version":"build-2736575974"},"reference-count":40,"publisher":"Informa Healthcare","issue":"16","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2015,11,2]]},"DOI":"10.1517\/14656566.2015.1099629","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T10:59:19Z","timestamp":1445252359000},"page":"2509-2522","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Review of vorapaxar for the prevention of atherothrombotic events"],"prefix":"10.1517","volume":"16","author":[{"given":"Amy","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"key":"CIT0001","first-page":"9e","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"Hoeben BJ","year":"2014"},{"key":"CIT0002","first-page":"18e","volume-title":"Harrison\u2019s principles of internal medicine","author":"Libby P","year":"2012"},{"key":"CIT0003","unstructured":"Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC\/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) [Internet]. American College of Cardiology Web Site. [cited 2015 Jan 31]. Available from: http:\/\/www.acc.org\/clinical\/guidelines\/pad\/index.pdf"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.004"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050522"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67660-X"},{"key":"CIT0011","unstructured":"FDA Approves Effient to Reduce the Risk of Heart Attack in Angioplasty Patients. FDA new release [Internet]. Silver Spring (MD): US Food and Drug Administration; 2009. [cited 2015 Jul 30]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm171497.htm"},{"key":"CIT0012","unstructured":"FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes. FDA news release [Internet]. Silver Spring (MD): US Food and Drug Administration; 2011. [cited 2015 Jul 30]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm263964.htm"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01377.x"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.574830"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603670"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1120-6"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1269-7"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.38"},{"issue":"1","key":"CIT0020","first-page":"S55","volume":"83","author":"Kosoglou T","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.035493"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1217-6"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109719"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.054"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.06.017"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.048"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht104"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200933"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61269-0"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013774"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.037"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000679"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.000433"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001505"},{"key":"CIT0035","unstructured":"Zontivity EPAR- Product Information [Internet]. London (UK): European Medicines Agency; 2015. [cited 2015 Aug 6] Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002814\/WC500183329.pdf"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.03.073"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.20"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.38"},{"key":"CIT0040","unstructured":"Vorapaxar: Zontivity [Internet]. London (UK): European Medicines Agency; 2015. [cited 2015 Jul 29]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002814\/human_med_001839.jsp&mid=WC0b01ac058001d124"},{"key":"CIT0042","unstructured":"FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients [Internet]. Silver Spring (MD): US Food and Drug Administration; 2014. [cited 2015 Aug 6]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm396585.htm"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2015.1099629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T14:15:03Z","timestamp":1481638503000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2015.1099629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,19]]},"references-count":40,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2015,9,11]]},"published-print":{"date-parts":[[2015,11,2]]}},"alternative-id":["10.1517\/14656566.2015.1099629"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2015.1099629","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}